Literature DB >> 14960127

Common fungal infections of the feet in patients with diabetes mellitus.

James S Tan1, Warren S Joseph.   

Abstract

Superficial fungal infections of the foot (tinea pedis and onychomycosis) are common among elderly patients. Although most authorities believe that patients with diabetes mellitus have an increased predisposition to dermatophytic infections, some controversies still remain. Because these infections disrupt the skin integrity and provide an avenue for bacterial superinfection, elderly diabetic patients with dermatophytic infection should be promptly treated with an antifungal agent. For most dermatophytic infections of the foot, topical agents are usually effective and less expensive than oral agents. Laboratory diagnosis of fungal infection prior to institution of therapy is recommended. Proper technique for obtaining the specimen is important to ensure a higher chance of isolating the infecting fungus. Commonly used anti-dermatophytic agents that are also active against the yeasts include the imidazoles, the allylamines-benzylamines and the hydroxypyridones, which are also effective against most of the moulds. Oral therapy for tinea pedis, although not well studied, should be limited to patients with more extensive infections, such as vesicobullous and moccasin type, resistant infections or chronic infections. In addition, oral agents should also be considered in diabetic and immunosuppressed patients. On the other hand, treatment of onychomycosis of the foot usually requires systemic therapy. Griseofulvin is the least effective agent when compared with the newer agents. Terbinafine, itraconazole and fluconazole have been shown to have acceptable cure rates. More recently, topical treatment of the nail with 8% ciclopirox nail lacquer, bifonazole with urea and amorolfine have been reported to be successful. Over the past decade, fungal foot infections of the skin and nail are more effectively treated with the introduction of numerous topical and oral agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14960127     DOI: 10.2165/00002512-200421020-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  58 in total

1.  Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach.

Authors:  E Alpsoy; E Yilmaz; E Basaran
Journal:  J Dermatol       Date:  1996-04       Impact factor: 4.005

Review 2.  A systematic review of oral treatments for fungal infections of the skin of the feet.

Authors:  S E Bell-Syer; R Hart; F Crawford; D J Torgerson; P Young; W Tyrrell; H Williams; I Russell
Journal:  J Dermatolog Treat       Date:  2001-06       Impact factor: 3.359

Review 3.  Onychomycosis and terbinafine.

Authors: 
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

4.  A comparison of bifonazole and ciclopiroxolamine: in vitro, animal, and clinical studies.

Authors:  H Hänel; B Abrams; W Dittmar; G Ehlers
Journal:  Mycoses       Date:  1988-12       Impact factor: 4.377

5.  Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial.

Authors:  B Farkas; C Paul; A Dobozy; J Hunyadi; A Horváth; G Fekete
Journal:  Br J Dermatol       Date:  2002-02       Impact factor: 9.302

Review 6.  Systemic drug photosensitivity.

Authors:  B Ljunggren; M Bjellerup
Journal:  Photodermatol       Date:  1986-02

7.  The safety of itraconazole in the diabetic population.

Authors:  D A Albreski; E G Gross
Journal:  J Am Podiatr Med Assoc       Date:  1999-07

Review 8.  Systemic antifungal agents. Drug interactions of clinical significance.

Authors:  E Albengres; H Le Louët; J P Tillement
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

9.  Diagnostic techniques for confirming onychomycosis.

Authors:  B E Elewski
Journal:  J Am Acad Dermatol       Date:  1996-09       Impact factor: 11.527

Review 10.  Treatment of onychomycosis: traditional approaches.

Authors:  G E Piérard; J Arrese-Estrada; C Piérard-Franchimont
Journal:  J Am Acad Dermatol       Date:  1993-07       Impact factor: 11.527

View more
  7 in total

1.  Pharmacokinetics of itraconazole in diabetic rats.

Authors:  Unji Lee; Young H Choi; So H Kim; Byung K Lee
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

2.  Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2.

Authors:  Y H Choi; U Lee; B K Lee; M G Lee
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 3.  Risk Factors and Comorbidities for Onychomycosis: Implications for Treatment with Topical Therapy.

Authors:  Boni E Elewski; Antonella Tosti
Journal:  J Clin Aesthet Dermatol       Date:  2015-11

4.  Onychomycosis in Older Adults: Prevalence, Diagnosis, and Management.

Authors:  Aditya K Gupta; Maanasa Venkataraman; Mesbah Talukder
Journal:  Drugs Aging       Date:  2022-02-01       Impact factor: 3.923

5.  Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review.

Authors:  Lisa Matricciani; Kerwin Talbot; Sara Jones
Journal:  J Foot Ankle Res       Date:  2011-12-04       Impact factor: 2.303

6.  Physicochemical and pathohistological changes in experimental fibrosarcoma tumors of hamsters treated with metformin and itraconazole.

Authors:  Kosta J Popović; Dušica J Popović; Dejan Miljković; Dušan Lalošević; Ivan Čapo; Jovan K Popović
Journal:  Oncol Lett       Date:  2019-06-21       Impact factor: 2.967

7.  The spectrum of cutaneous infection in diabetic patients with hepatitis C virus infection: a single-center study from egypt.

Authors:  Mohamed A El-Khalawany; Ali M Mahmoud
Journal:  Indian J Dermatol       Date:  2014-05       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.